Respiratory

Respiratory - commissioning policies

Please click on the links below to access the commissioning policies. The associated Equality Impact Assessments, if currently available, are accessible here.

The CCGs’ position on the implementation of policies affecting patient referral can be found here.
Aclidinium inhalation powder for Chronic Obstructive Pulmonary Disease Fluticasone furoate and vilanterol trifenatate (Relvar® Ellipta®) combination inhaler for asthma Fluticasone furoate and vilanterol trifenatate (Relvar® Ellipta®) combination inhaler for Chronic Obstructive Pulmonary Disease Flutiform® for the treatment of asthma in adults and children over 12 years Glycopyrronium inhalation powder therapy for Chronic Obstructive Pulmonary Disease Indacaterol inhalation powder hard capsules for Chronic Obstructive Pulmonary disease Tiotropium bromide monohydrate and olodaterol hydrochloride (Spiolto® Respimat®) combination inhaler for Chronic Obstructive Pulmonary Disease

Please note:  Some commissioning policies approved by the previous commissioning organisations are yet to be reviewed and updated. There is an on-going programme of work in place to review and update these policies. They will then be published under the appropriate category. 

In the meantime they are still applicable to Northern, Eastern and Western Devon CCG. Former NHS Devon policies can be accessed here

Rate this page